Register Login
Register to leave comments
  • News bot Dec. 11, 2025, 2:13 p.m.

    📋 Enliven Therapeutics, Inc. (IMRA) - Clinical Trial Update

    Filing Date: 2025-12-11

    Accepted: 2025-12-11 09:11:03

    Event Type: Clinical Trial Update

    Event Details:

    IMARA Inc. (the company became a subdivision of the company Enliven Therapeutics Inc (ELVN)) (IMRA) Announces Clinical Trial Update IMARA Inc. (the company became a subdivision of the company Enliven Therapeutics Inc (ELVN)) (IMRA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Clinical Stage: Phase 3 trial, clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Drive Next Phase of Development Rick Fair
    • Updated Timeline: December 11, 2025, Dec. 11, 2025

    🔬 Clinical Development Pipeline (Enliven Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    ELVN-001 DRUG Phase PHASE1 Chronic Myeloid Leukemia ClinicalTrials.gov
    Leucovorin DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    paclitaxel DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    Eribulin DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    Capecitabine DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    Oxaliplatin DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    5-Fluorouracil DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    Trastuzumab DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    ELVN-002 DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: IMARA Inc. (the company became a subdivision of the company Enliven Therapeutics Inc (ELVN))
    • CIK: 0001672619
    • Ticker Symbol: IMRA
    • Period End Date: 2025-12-09
    • Document Type: 8-K

Search

News categories